The effect of montelukast on respiratory symptoms and lung function in wheezy infants

Pelkonen, Antti; Malmström, Kristiina; Sarna, Seppo; Kajosaari, Merja; Klemola, Timo; Malmberg, L. Pekka; Mäkelä, Mika J.

doi:10.1183/09031936.00173411

Cited by 23 publications

(19 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Infant lung function testing has been used to define phenotypes in infants with wheeze and to predict treatment effects and prognosis [120,121,[123][124][125]; several studies have tracked lung function from infancy to school age [115-117, 119, 126-131]. However, at present there is no data to support the clinical use of infant lung function tests for monitoring wheezing infants.…”

Section: Infant Lung Functionmentioning

confidence: 96%

Monitoring asthma in children

et al. 2015

Self Cite

View full text Add to dashboard Cite

The goal of asthma treatment is to obtain clinical control and reduce future risks to the patient. To reach this goal in children with asthma, ongoing monitoring is essential. While all components of asthma, such as symptoms, lung function, bronchial hyperresponsiveness and inflammation, may exist in various combinations in different individuals, to date there is limited evidence on how to integrate these for optimal monitoring of children with asthma. The aims of this ERS Task Force were to describe the current practise and give an overview of the best available evidence on how to monitor children with asthma.22 clinical and research experts reviewed the literature. A modified Delphi method and four Task Force meetings were used to reach a consensus.This statement summarises the literature on monitoring children with asthma. Available tools for monitoring children with asthma, such as clinical tools, lung function, bronchial responsiveness and inflammatory markers, are described as are the ways in which they may be used in children with asthma. Management-related issues, comorbidities and environmental factors are summarised.Despite considerable interest in monitoring asthma in children, for many aspects of monitoring asthma in children there is a substantial lack of evidence. @ERSpublications ERS statement summarising and discussing the available literature on monitoring children with asthma

show abstract

Section: Infant Lung Functionmentioning

confidence: 96%

Monitoring asthma in children

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Reduced lung function in infancy was associated with respiratory morbidity and treatment needs at preschool age [65]. Some studies showed improvement of lung function, such as forced expiratory volume in 0.5 s, in infants with recurrent wheezing after ICS treatment or oral treatment with montelukast, whereas others did not show significant changes [63,64,74,75].…”

Section: Infant Lung Functionmentioning

confidence: 99%

Monitoring asthma in childhood: lung function, bronchial responsiveness and inflammation

et al. 2015

View full text Add to dashboard Cite

This review focuses on the methods available for measuring reversible airways obstruction, bronchial hyperresponsiveness (BHR) and inflammation as hallmarks of asthma, and their role in monitoring children with asthma. Persistent bronchial obstruction may occur in asymptomatic children and is considered a risk factor for severe asthma episodes and is associated with poor asthma outcome. Annual measurement of forced expiratory volume in 1 s using office based spirometry is considered useful. Other lung function measurements including the assessment of BHR may be reserved for children with possible exercise limitations, poor symptom perception and those not responding to their current treatment or with atypical asthma symptoms, and performed on a higher specialty level. To date, for most methods of measuring lung function there are no proper randomised controlled or large longitudinal studies available to establish their role in asthma management in children.Noninvasive biomarkers for monitoring inflammation in children are available, for example the measurement of exhaled nitric oxide fraction, and the assessment of induced sputum cytology or inflammatory mediators in the exhaled breath condensate. However, their role and usefulness in routine clinical practice to monitor and guide therapy remains unclear, and therefore, their use should be reserved for selected cases. @ERSpublications Review on the role of lung function, measurement of BHR and airway inflammation in monitoring of children with asthma

show abstract

“…Initially, Bisgaard et al conducted a randomized, double‐blinded study of children aged 3‐36 months in the post‐infectious period of RSV bronchiolitis and found that the proportion of symptom‐free infants was significantly higher for the montelukast than for the placebo group during a 28‐day treatment period (22% vs 4%, respectively). However, a large multicenter and long‐term study by the same team and a double‐blinded, randomized controlled study, failed to replicate these findings. Our findings are consistent with a recent meta‐analysis and a Cochrane review that found no effect of montelukast treatment on SFD, or the need for corticosteroids and recurrence of wheezing episodes compared with placebo for children aged less than 2 with post‐bronchiolitis.…”

Section: Discussionmentioning

confidence: 99%